Chinese expert consensus on the diagnosis and management of elderly patients with diffuse large B-cell lymphoma(2024)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
随着人口老龄化来临,老年弥漫大B细胞淋巴瘤(Diffuse large B cell lymphoma,DLBCL)患者比例上升.老年患者对治疗耐受性差,治疗方案需要个体化制定.为提高我国临床医师对老年DLBCL的诊断及治疗水平,中华医学会血液病学分会淋巴细胞疾病学组和中国临床肿瘤学会(CSCO)淋巴瘤专家委员会组织相关专家制定了本共识.
The general population in China is aging,and thus the number of older patients with diffuse large B-cell lymphoma(DLBCL)will continue to increase.Individualized treatment is required to maximize therapeutic potential while minimizing the risk of toxicity.To improve the diagnosis and treatment of DLBCL in older people in China,the Lymphocyte Disease Group of the Hematology Division of the Chinese Medical Association and Lymphoma Expert Commitee of Chinese Society of Clinical Oncology(CSCO)have organized relevant experts to formulate this consensus.
NETL
NSTL
万方数据
